Denstu Ventures, the investment arm of Dentsu, has invested in Cue, a device that allows people to track health changes at a molecular level at home via a smartphone app.
The device allows people to track changes such as levels of vitamin D, testosterone, inflammation, influenza and fertility by taking a small sample of blood, saliva or mucus that has been collected and added to a colour-coded cartridge which is then inserted into the Cue hardware device.
The level of investment hasn’t been disclosed but Dentsu said that much like its other investments, in addition to funding, it will also provide support Read full story ›
Source: The Drum
Industry News